2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Vaccines, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, MPN, CML, Study Population, Human, Adult, Animal Model
PAPER

3741 Comparison of CALRdel52 knock-in mouse models in Mx1-cre and vav-cre backgrounds reveals poly I:C-dependent confounding of MPN disease progression

Maihi Skeen, BS, Nicole S. Arellano, MS2, Juan Li, PhD3, Anton Rets, MD, PhD4, Shannon E Elf, PhD5
1 Huntsman Cancer Institute - Cancer Research North, Salt Lake City, Utah, United States
2 Huntsman Cancer Institute - Cancer Research North, Salt Lake City, Utah, United States
3 Jeffrey Cheah Biomedical Centre, Cambridge, United Kingdom
4 ARUP Laboratories, Salt Lake City, Utah, United States
5 Huntsman Cancer Institute - Cancer Research North, Salt Lake City, Utah, United States

Introduction:
Calreticulin (CALR) mutations are the second most common driver of BCR::ABL1-negative myeloproliferative neoplasms (MPNs). The widely used CALRdel52 knock-in mouse model employs Mx1-Cre-mediated recombination to induce mutant CALR expression; however, induction requires polyinosinic:polycytidylic acid (poly I:C), which elicits systemic interferon signaling, causing acute hematopoietic suppression, weight loss, and potentially confounding disease phenotypes. We therefore compared disease progression in CALRdel52 mice crossed with inducible Mx1-Cre or constitutive Vav-Cre, which eliminates the need for poly I:C-mediated induction. We also evaluated three poly I:C dosing regimens to determine whether reduced inflammatory signaling could improve the Mx1-Cre model while preserving recombination efficiency.

Additionally, although the CALRdel52/Mx1-Cre model has been widely used to study ET and MF, it remains unknown whether these mice progress through a bona fide pre-fibrotic MF stage, representing a major gap in current MPN mouse models and limiting mechanistic studies of disease progression. We therefore asked whether either the Mx1-Cre or Vav-Cre model recapitulates this stage. Identification of a pre-fibrotic MF stage would establish a window to investigate the mechanisms driving progression from ET to pre-fibrotic MF and ultimately overt MF, as well as to evaluate therapeutic strategies that prevent disease progression.

Methods:
CALRdel52 knock-in mice were crossed with Mx1-Cre or Vav-Cre mice. Homozygous, heterozygous, and wild-type littermates were analyzed. Mx1-Cre mice received one of three poly I:C dosing regimens. Body weight and complete blood counts were serially monitored. Genomic recombination was assessed by PCR, and spleen, liver, and femurs were analyzed histologically.

Results:
In the Mx1-Cre cohort, poly I:C induction significantly influenced body weight and hematologic parameters in CALRdel52 mice, with effects proportional to dose. Mice receiving 10 mg/kg poly I:C lost 15-20% of body weight following the initial injection, whereas 1 mg/kg caused minimal weight loss. Although transient leukopenia was anticipated after poly I:C administration, white blood cell counts showed no consistent decline across dosing groups. Platelet counts demonstrated the greatest phenotypic differences. Lower poly I:C doses produced a more rapid rise in platelet counts, whereas higher doses attenuated thrombocytosis, suggesting that interferon-driven inflammation suppresses the CALRdel52 disease phenotype. Genomic PCR demonstrated that there is no significant in difference in recombination across dosing groups. This suggests that the 1 mg/kg dose of poly I:C is optimal to balance sufficient recombination with suppression of hematopoiesis and weight loss.

In the Mx1-Cre cohort, thrombocytosis developed as early as 6 weeks after 1 mg/kg poly I:C induction in homozygous mice and 7 weeks in heterozygous mice. Platelet counts in heterozygous mice plateaued at approximately 2,000 ± 500 × 10³/µL by 12 weeks, whereas homozygous mice exhibited progressive thrombocytosis throughout the study. Histopathologic analysis identified a pre-fibrotic stage by 3 months in homozygous mice receiving 1 mg/kg poly I:C. In contrast, disease progression was delayed by approximately 1-2 months in mice receiving 10 mg/kg poly I:C, consistent with higher dose poly I:C suppressing the CALRdel52 disease phenotype.

By comparison, Vav-Cre mice developed thrombocytosis by 5 weeks in both homozygous and heterozygous animals without poly I:C-induced toxicity. Platelet counts in heterozygous mice plateaued at approximately 2,000 ± 200 × 10³/µL by 7 weeks, whereas homozygous mice exhibited progressive thrombocytosis and developed histologic features consistent with pre-fibrotic myelofibrosis by 2 months, approximately one month earlier than observed in the Mx1-Cre model.

Conclusions:
Poly(I:C) substantially alters the hematologic phenotype of CALRdel52-driven MPN, potentially confounding studies using the Mx1-Cre model. In contrast, CALRdel52/Vav-Cre mice develop disease without inflammatory induction, providing a more physiologically relevant and reproducible model of CALR-mutant MPN. Importantly, we identified a bona fide pre-fibrotic MF stage, establishing a platform for mechanistic studies of disease progression and evaluation of therapies that prevent progression to overt MF.

Maihi Skeen, BS: No relevant conflicts of interest to declare.